Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications

Ruth Halaban, Michael Krauthammer, Mattia Pelizzola et al. · 2009

Read Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications by Ruth Halaban, Michael Krauthammer, Mattia Pelizzola et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004563.txt.

Description

Melanoma cells answer a gene-awakening drug in varied ways that may predict who benefits, report Ruth Halaban, Michael Krauthammer, Mattia Pelizzola, and co-authors in PLOS ONE in 2009. The drug is decitabine. It reactivates genes silenced by DNA methylation, a chemical mark that can shut genes off in cancer.

Decitabine helps some cancer patients but not others, especially those with solid tumors. The team carried out an integrative analysis of how melanoma cells respond at the epigenetic level, the level of marks rather than the DNA code itself. Patterns in that response carry clinical implications: they may separate likely responders from patients who would only suffer side effects. Such sorting is the heart of personalized cancer care.

Catalog record

CREATORRuth Halaban, Michael Krauthammer, Mattia Pelizzola et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE66 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004563

Browse the full library · About the Tower of Babel